Literature DB >> 1605252

Molecular genetic and immunological analysis of dystrophin of a young patient with X-linked muscular dystrophy.

K Ikeya1, K Saito, K Hayashi, H Tanaka, Y Hagiwara, M Yoshida, A Yamauchi, Y Fukuyama, T Ishiguro, C Eguchi.   

Abstract

We examined the nucleotide sequence of deleted part of dystrophin mRNA and its translational product with immunoblot and immunohistochemical methods in a 6-year-old boy with a deleted DMD/BMD gene. On Southern blot analysis of his genomic DNA, we found a deletion of exons 10 to 37 in the DMD/BMD gene, which was expected to preserve the translational open reading frame (ORF). Dystrophin mRNA from his biopsy sample was amplified by polymerase chain reaction (PCR) and sequenced. The mRNA lacked the sequence corresponding to the gene from exons 10-37, and the translational ORF was preserved. The transcript was expected to code a 260 kDa protein. Dystrophin expressed in this patient was investigated with immunological methods. A 260 kDa protein was detected by immunoblot analysis with antidystrophin antiserum against nondeleted regions. These observations confirmed the preservation of the reading frame and the 260 kDa protein was produced as a mutant dystrophin. All these are compatible with the diagnosis of BMD. However, the immunohistochemical pattern of his muscle cells was peculiar. With deleted-region-directed antiserum, the membrane was not stained at all as in DMD patients. In contrast, with nondeleted-region-directed antiserum, all the muscle cell membrane was stained continuously as in non-DMD/BMD individuals. These are quite different from the staining pattern in most BMD patients where muscles are stained patchily or discontinuously.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605252     DOI: 10.1002/ajmg.1320430315

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

1.  Mild deficiency of dystrophin-associated proteins in Becker muscular dystrophy patients having in-frame deletions in the rod domain of dystrophin.

Authors:  K Matsumura; I Nonaka; F M Tomé; K Arahata; H Collin; F Leturcq; D Récan; J C Kaplan; M Fardeau; K P Campbell
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

Review 2.  Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Dongsheng Duan
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

3.  Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin.

Authors:  K Matsumura; A H Burghes; M Mora; F M Tomé; L Morandi; F Cornello; F Leturcq; M Jeanpierre; J C Kaplan; P Reinert
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.